CABA Cabaletta Bio Inc

Price (delayed)

$7.82

Market cap

$377.52M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.72

Enterprise value

$210.4M

Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, ...

Highlights
The equity has soared by 142% YoY but it has contracted by 6% from the previous quarter
Cabaletta Bio's quick ratio has increased by 23% YoY but it has decreased by 17% QoQ
CABA's debt has surged by 75% year-on-year and by 63% since the previous quarter
CABA's net income is down by 38% year-on-year and by 14% since the previous quarter

Key stats

What are the main financial stats of CABA
Market
Shares outstanding
48.28M
Market cap
$377.52M
Enterprise value
$210.4M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.7
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$76.87M
EBITDA
-$72.37M
Free cash flow
-$66.05M
Per share
EPS
-$1.72
Free cash flow per share
-$1.37
Book value per share
$4.6
Revenue per share
$0
TBVPS
$4.98
Balance sheet
Total assets
$240.46M
Total liabilities
$18.74M
Debt
$8.17M
Equity
$221.72M
Working capital
$209.51M
Liquidity
Debt to equity
0.04
Current ratio
12.66
Quick ratio
12.46
Net debt/EBITDA
2.31
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-36.1%
Return on equity
-38.8%
Return on invested capital
-147.5%
Return on capital employed
-34.5%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CABA stock price

How has the Cabaletta Bio stock price performed over time
Intraday
-5.1%
1 week
3.44%
1 month
-26.64%
1 year
-35.43%
YTD
-65.55%
QTD
4.55%

Financial performance

How have Cabaletta Bio's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$85.74M
Net income
-$76.87M
Gross margin
N/A
Net margin
N/A
The operating income has contracted by 48% YoY and by 15% from the previous quarter
CABA's net income is down by 38% year-on-year and by 14% since the previous quarter

Growth

What is Cabaletta Bio's growth rate over time

Valuation

What is Cabaletta Bio stock price valuation
P/E
N/A
P/B
1.7
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
CABA's EPS is up by 5% YoY but it is down by 4.2% QoQ
The equity has soared by 142% YoY but it has contracted by 6% from the previous quarter
CABA's price to book (P/B) is 49% lower than its last 4 quarters average of 3.5 and 19% lower than its 5-year quarterly average of 2.2

Efficiency

How efficient is Cabaletta Bio business performance
Cabaletta Bio's ROE has increased by 34% YoY and by 4.9% from the previous quarter
Cabaletta Bio's return on assets has increased by 33% YoY and by 4.7% QoQ
The ROIC has grown by 28% YoY and by 14% from the previous quarter

Dividends

What is CABA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CABA.

Financial health

How did Cabaletta Bio financials performed over time
Cabaletta Bio's total assets has soared by 132% YoY but it has decreased by 5% from the previous quarter
Cabaletta Bio's total liabilities has soared by 59% YoY and by 7% from the previous quarter
CABA's debt is 96% smaller than its equity
The equity has soared by 142% YoY but it has contracted by 6% from the previous quarter
Cabaletta Bio's debt to equity has soared by 100% from the previous quarter but it has decreased by 20% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.